$16.78
0.12% yesterday
NYSE, Oct 23, 10:00 pm CET
ISIN
US03969F1093
Symbol
RCUS

Arcus Biosciences Stock price

$16.78
+4.39 35.43% 1M
+8.67 106.91% 6M
+1.89 12.69% YTD
-0.55 3.17% 1Y
-11.02 39.64% 3Y
-3.36 16.68% 5Y
-0.22 1.29% 10Y
-0.22 1.29% 20Y
NYSE, Closing price Thu, Oct 23 2025
-0.02 0.12%

Key metrics

Basic
Market capitalization
$1.8b
Enterprise Value
$971.9m
Net debt
positive
Cash
$911.0m
Shares outstanding
106.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.8 | 7.6
EV/Sales
3.7 | 4.1
EV/FCF
negative
P/B
3.3
Financial Health
Equity Ratio
42.2%
Return on Equity
-58.4%
ROCE
-39.1%
ROIC
-529.9%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$262.0m | $236.1m
EBITDA
$-328.0m | $-376.4m
EBIT
$-338.0m | $-421.9m
Net Income
$-298.0m | $-409.0m
Free Cash Flow
$-342.0m
Growth (TTM | estimate)
Revenue
6.1% | -8.5%
EBITDA
-24.2% | -25.5%
EBIT
-23.8% | -36.1%
Net Income
-19.7% | -44.5%
Free Cash Flow
-28.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-125.2% | -159.4%
EBIT
-129.0%
Net
-113.7% | -173.2%
Free Cash Flow
-130.5%
More
EPS
$-2.8
FCF per Share
$-3.2
Short interest
14.2%
Employees
627
Rev per Employee
$410.0k
Show more

Is Arcus Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.

Arcus Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Arcus Biosciences forecast:

16x Buy
84%
3x Hold
16%

Analyst Opinions

19 Analysts have issued a Arcus Biosciences forecast:

Buy
84%
Hold
16%

Financial data from Arcus Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
262 262
6% 6%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 115 115
5% 5%
44%
- Research and Development Expense 485 485
22% 22%
185%
-328 -328
24% 24%
-125%
- Depreciation and Amortization 10 10
11% 11%
4%
EBIT (Operating Income) EBIT -338 -338
24% 24%
-129%
Net Profit -298 -298
20% 20%
-114%

In millions USD.

Don't miss a Thing! We will send you all news about Arcus Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcus Biosciences Stock News

Neutral
Business Wire
5 days ago
TOKYO & HAYWARD, Calif.--(BUSINESS WIRE)--Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences, Inc. (NYSE:RCUS, “Arcus”) announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan (International Nonproprietary Name; development code: AB521), an investigational small molecule HIF (Hypoxia Inducible Factor)-2α inhibitor, in Japan and certain other t...
Positive
Seeking Alpha
8 days ago
Arcus Biosciences (RCUS) boasts a diverse, promising pipeline with key candidates like domvanalimab, casdatifan, and quemliclustat advancing in pivotal trials. Recent data from RCUS's EDGE-Gastric trial show strong survival benefits, with major readouts from large phase 3 studies expected in 2026. RCUS is well-capitalized with nearly $1 billion in liquid assets, but its high cash burn suggests ...
Neutral
Business Wire
12 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced the first OS results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junct...
More Arcus Biosciences News

Company Profile

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Head office United States
CEO Terry Rosen
Employees 627
Founded 2015
Website arcusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today